(+)-[18F]Flubatine作为新型α4β2烟碱型乙酰胆碱受体PET显像剂:首例人体脑成像在β-淀粉样蛋白PET确诊的阿尔茨海默病患者与健康对照中的结果
本研究首次在人体中评估新型α4β2烟碱型乙酰胆碱受体PET显像剂(+)-[18F]Flubatine,纳入11例健康对照和9例轻度阿尔茨海默病患者,所有受试者接受神经心理测试和[11C]PiB PET/MRI。结果显示(+)-[18F]Flubatine安全稳定,可采用1组织隔室模型(无需代谢物校正)进行全动力学建模,阿尔茨海默病患者双侧内侧颞叶皮层分布容积显著降低,且部分脑区结合与认知测试及β-淀粉样蛋白沉积相关。
要点
- (+)-[18F]Flubatine安全稳定,1TCM无需代谢物校正即可全动力学建模。
- 阿尔茨海默病患者双侧内侧颞叶皮层(+)-[18F]Flubatine结合显著降低。
- 部分脑区结合与认知测试相关,白质β-淀粉样蛋白沉积与结合相关。
核心结论
- (+)-[18F]Flubatine是安全稳定的PET配体,结合亲和力足以检测组间差异,有潜力作为α4β2 nAChR靶向PET配体用于进一步临床试验。
研究设计与样本
- 研究纳入11例健康对照和9例轻度阿尔茨海默病患者,所有受试者接受神经心理测试和[11C]PiB PET/MRI检查。
- (+)-[18F]Flubatine PET数据采用全动力学建模以及区域和基于体素的分析进行评估。
主要发现
- 注射后270分钟,未改变母体化合物占比为97±2%。
- 时间-放射性曲线可用1组织隔室模型(1TCM)获得充分拟合。
- 阿尔茨海默病患者双侧内侧颞叶皮层(+)-[18F]Flubatine分布容积(结合)较健康对照显著降低:右侧10.6±1.1 vs 11.6±1.4,p=0.049;左侧11.0±1.1 vs 12.2±1.8,p=0.046(单侧t检验)。
- 部分容积效应(PVE)校正使(+)-[18F]Flubatine结合增加约15%,标准差增加0.4-70%。
- 认知测试数据与(+)-[18F]Flubatine结合在左侧前扣带回、右侧后扣带回和右侧顶叶皮层显著相关(r>0.5,p<0.05)。
临床怎么用
- (+)-[18F]Flubatine可作为α4β2 nAChR靶向PET配体用于进一步临床试验。
- 全动力学建模可采用1TCM且无需代谢物校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSES: We present the first in-human brain PET imaging data of the new α4β2 nicotinic acetylcholine receptor (nAChR)-targeting radioligand (+)-[18F]Flubatine. Aims were to develop a kinetic modeling-based approach to quantify (+)-[18F]Flubatine and compare the data of healthy controls (HCs) and patients with Alzheimer's disease (AD); to investigate the partial volume effect (PVE) on regional (+)-[18F]Flubatine binding; and whether (+)-[18F]Flubatine binding and cognitive test data respective β-amyloid radiotracer accumulation were correlated. METHODS: We examined 11 HCs and 9 mild AD patients. All subjects underwent neuropsychological testing and [11C]PiB PET/MRI examination. (+)-[18F]Flubatine PET data were evaluated using full kinetic modeling and regional as well as voxel-based analyses. RESULTS: With 270-min p.i., the unchanged parent compound amounted to 97 ± 2%. Adequate fits of the time-activity curves were obtained with the 1 tissue compartment model (1TCM). (+)-[18F]Flubatine distribution volume (binding) was significantly reduced in bilateral mesial temporal cortex in AD patients compared with HCs (right 10.6 ± 1.1 vs 11.6 ± 1.4, p = 0.049; left 11.0 ± 1.1 vs 12.2 ± 1.8, p = 0.046; one-sided t tests each). PVE correction increased not only (+)-[18F]Flubatine binding of approximately 15% but also standard deviation of 0.4-70%. Cognitive test data and (+)-[18F]Flubatine binding were significantly correlated in the left anterior cingulate, right posterior cingulate, and right parietal cortex (r > 0.5, p < 0.05 each). In AD patients, (+)-[18F]Flubatine binding and [11C]PiB standardized uptake value ratios were negatively correlated in several regions; whereas in HCs, a positive correlation between cortical (+)-[18F]Flubatine binding and [11C]PiB accumulation in the white matter was found. No adverse event related to (+)-[18F]Flubatine occurred. CONCLUSION: (+)-[18F]Flubatine is a safe and stable PET ligand. Full kinetic modeling can be realized by 1TCM without metabolite correction. (+)-[18F]Flubatine binding affinity was high enough to detect group differences. Of interest, correlation between white matter β-amyloid PET uptake and (+)-[18F]Flubatine binding indicated an association between white matter integrity and availability of α4β2 nAChRs. Overall, (+)-[18F]Flubatine showed favorable characteristics and has therefore the potential to serve as α4β2 nAChR-targeting PET ligand in further clinical trials.
引用
- Tiepolt S, Becker GA, Wilke S, et al. (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2020. PMID: 32935187. doi:10.1007/s00259-020-05029-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。